secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apyx Medical Corp (APYX)
CIK:        0000719135
Form:       8-K
Filed at:   2026-03-10T23:59:59+00:00
Accession:  0001437749-26-007420
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apyx Medical Q4 revenue record $19.2M, net loss narrows; FY2026 guidance $57.5-58.5M
--------------------------------------------------------------------------------

- Q4 total revenue record $19.2M, +34.7% YoY; Surgical Aesthetics +38.1% to $16.7M driven by AYON launch.
- Q4 net loss narrowed to $1.3M ($0.03/sh) from $4.6M ($0.12/sh); Adjusted EBITDA $0.7M vs ($2.2M).
- FY2025 total revenue $52.8M (+9.9% YoY); net loss $11.2M ($0.27/sh) vs $23.5M ($0.66/sh) in 2024.
- FY2026 guidance: total revenue $57.5M-$58.5M; Surgical Aesthetics rev $53M-$54M; OEM rev ~$4.5M.
- Submitted 510(k) for AYON power liposuction label expansion; clearance anticipated mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/719135/000143774926007420/0001437749-26-007420-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/719135/000143774926007420/apyx20250930_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-007420

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer